BR112015011033A2 - derivado aldeído de oxazolidinonas substituídas - Google Patents

derivado aldeído de oxazolidinonas substituídas

Info

Publication number
BR112015011033A2
BR112015011033A2 BR112015011033A BR112015011033A BR112015011033A2 BR 112015011033 A2 BR112015011033 A2 BR 112015011033A2 BR 112015011033 A BR112015011033 A BR 112015011033A BR 112015011033 A BR112015011033 A BR 112015011033A BR 112015011033 A2 BR112015011033 A2 BR 112015011033A2
Authority
BR
Brazil
Prior art keywords
oxo
aldehyde derivative
substituted oxazolidinones
oxazolidin
carboxamide
Prior art date
Application number
BR112015011033A
Other languages
English (en)
Inventor
Pawar Sandip Babanrao
Walavalkar Rajesh Ramchandra
Pawar Tarak Sambhaji
Pradhan Nitin Sharadchandra
Kulkarni Nilesh Subhas
Patil Nilesh Sudhir
Original Assignee
Wanbury Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wanbury Ltd filed Critical Wanbury Ltd
Publication of BR112015011033A2 publication Critical patent/BR112015011033A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

resumo "derivado aldeído de oxazolidinonas substituídas" fórmula (b) a presente invenção se refere ao promedicamento 5-cloro-n-({(5s)-2-oxo-3-[4-(3-oxo-morfolin-4-il)fenil]-1,3-oxazolidin-5-il}metil)tiofeno-2-carboxamida, propriamente o rivaroxabano, aos processos para a sua preparação, bem como a aplicação no tratamento e/ou profilaxia de doenças, especialmente transtornos tromboembólicos. o pró-fármaco do composto da fórmula (b) é quimicamente denominado como 5-cloro-n-formil-n-({(5s)-2-oxo-3-[4-(3-oxomorfolin-4-il)fenil]-1,3-oxazolidin-5-il} metil) tiofeno-2-carboxamida (i).
BR112015011033A 2012-12-26 2013-12-24 derivado aldeído de oxazolidinonas substituídas BR112015011033A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN3359MU2012 IN2012MU03359A (pt) 2012-12-26 2013-12-24
PCT/IN2013/000801 WO2014102822A2 (en) 2012-12-26 2013-12-24 Aldehyde derivative of substitute oxazolidinones

Publications (1)

Publication Number Publication Date
BR112015011033A2 true BR112015011033A2 (pt) 2017-07-11

Family

ID=54242230

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015011033A BR112015011033A2 (pt) 2012-12-26 2013-12-24 derivado aldeído de oxazolidinonas substituídas

Country Status (15)

Country Link
US (1) US9359341B2 (pt)
EP (1) EP2897619A4 (pt)
JP (1) JP2016504348A (pt)
KR (1) KR20150100661A (pt)
CN (1) CN105431429A (pt)
AU (1) AU2013368847B2 (pt)
BR (1) BR112015011033A2 (pt)
CA (1) CA2883323A1 (pt)
HK (1) HK1217101A1 (pt)
IN (1) IN2012MU03359A (pt)
MX (1) MX2015003319A (pt)
PH (1) PH12015501625A1 (pt)
RU (1) RU2015112195A (pt)
WO (1) WO2014102822A2 (pt)
ZA (1) ZA201503700B (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014102820A2 (en) * 2012-12-26 2014-07-03 Wanbury Ltd. Rivaroxaban intermediate and preparation thereof
US20160251342A1 (en) * 2012-12-26 2016-09-01 Wanbury Ltd. Aldehyde derivative of substituted oxazolidinones

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19962924A1 (de) 1999-12-24 2001-07-05 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
DE10129725A1 (de) * 2001-06-20 2003-01-02 Bayer Ag Kombinationstherapie substituierter Oxazolidinone
DE10300111A1 (de) 2003-01-07 2004-07-15 Bayer Healthcare Ag Verfahren zur Herstellung von 5-Chlor-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamid
DE102004002044A1 (de) 2004-01-15 2005-08-04 Bayer Healthcare Ag Herstellverfahren
GT200600196A (es) * 2005-05-23 2007-01-15 Compuestos n-formil de hidroxilamina
DE102005045518A1 (de) 2005-09-23 2007-03-29 Bayer Healthcare Ag 2-Aminoethoxyessigsäure-Derivate und ihre Verwendung
RU2429236C2 (ru) 2005-10-04 2011-09-20 Байер Шеринг Фарма Акциенгезельшафт Новая полиморфная форма и аморфная форма 5-хлор-n-({(5s)-2-оксо-3-[4-(3-оксо-4-морфолинил)-фенил]-1, 3-оксазолидин-5-ил}-метил)-2-тиофенкарбоксамида
DE102006007146A1 (de) 2006-02-16 2007-08-23 Bayer Healthcare Ag Aminoacyl-Prodrugs
DE102006039589A1 (de) * 2006-08-24 2008-03-06 Bayer Healthcare Ag Aminoacyl-Prodrugs II
ES2425183T3 (es) 2007-08-14 2013-10-11 Concert Pharmaceuticals Inc. Derivados de oxazolidinonas sustituidas
US7816355B1 (en) 2009-04-28 2010-10-19 Apotex Pharmachem Inc Processes for the preparation of rivaroxaban and intermediates thereof
EA031064B2 (ru) 2009-07-31 2020-07-01 КРКА, д.д., НОВО МЕСТО Способы кристаллизации ривароксабана
US20120283434A1 (en) 2010-01-04 2012-11-08 Enantia, S.L. Process for the preparation of rivaroxaban and intermediates thereof
EP2354128A1 (en) 2010-02-10 2011-08-10 Sandoz Ag Method for the preparation of rivaroxaban
EA201370107A1 (ru) * 2010-11-11 2013-11-29 Редкс Фарма Лимитед Производные лекарственных средств
EP2697209B1 (en) 2011-04-11 2015-09-23 Sandoz AG Method for the preparation of substituted oxazolidinones
JP6325978B2 (ja) 2011-05-06 2018-05-16 エギシュ ヂョヂセルヂャール ザートケルエン ミケデ レースヴェーニタールササーグ リバロキサバンの製法及び該方法において形成される中間体
ES2395304B1 (es) 2011-05-20 2014-01-16 Interquim, S.A. Procedimiento de obtención de una tiofen-2-carboxamida.
WO2014102820A2 (en) 2012-12-26 2014-07-03 Wanbury Ltd. Rivaroxaban intermediate and preparation thereof

Also Published As

Publication number Publication date
JP2016504348A (ja) 2016-02-12
HK1217101A1 (zh) 2016-12-23
RU2015112195A (ru) 2017-01-31
EP2897619A2 (en) 2015-07-29
WO2014102822A2 (en) 2014-07-03
ZA201503700B (en) 2016-10-26
EP2897619A4 (en) 2016-08-17
CA2883323A1 (en) 2014-07-03
KR20150100661A (ko) 2015-09-02
US20150259333A1 (en) 2015-09-17
US9359341B2 (en) 2016-06-07
AU2013368847B2 (en) 2017-03-16
PH12015501625A1 (en) 2015-09-28
MX2015003319A (es) 2015-08-14
WO2014102822A3 (en) 2015-10-29
AU2013368847A1 (en) 2015-05-28
IN2012MU03359A (pt) 2015-06-26
CN105431429A (zh) 2016-03-23

Similar Documents

Publication Publication Date Title
ATE545645T1 (de) Neue cokristall-verbindung von rivaroxaban und malonsäure
HK1130252A1 (en) Aminoacyl prodrug derivatives and medicaments for the treatment of thromboembolitic disorders
DK1934208T3 (da) Ny polymorf form af 5-chlor-N-({(5S)-2-0x0-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamid
AR116394A2 (es) Mesilato de n-[5-(aminosulfonil)-4-metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)fenil]acetamida monohidrato
EA201391647A1 (ru) Способ получения ривароксабана и промежуточные соединения, получаемые в указанном способе
CR20150001A (es) Formas de administración farmacéuticas que comprenden 5-cloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morfolinil) fenil]-1,3-oxazolidin-5-il}metil)-2-tiofencarboxamida
BRPI0519376A2 (pt) formas de administraÇço farmacÊuticas sàlidas, aplicÁveis por via oral, contendo rivaroxaban com liberaÇço modificada
BRPI0418405A (pt) processo de preparação
MX2009001977A (es) Derivados profarmacologicos de aminoacilo y medicamentos para el tratamiento de enfermedades tromboembolicas.
BR112015011033A2 (pt) derivado aldeído de oxazolidinonas substituídas
WO2012080184A3 (de) Flüssige, oral applizierbare pharmazeutische zusammensetzungen enthaltend 5-chlor-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamid
BR112016024825A2 (pt) composição contendo rivaroxaban e processo para fabricação de uma composição compreendendo rivaroxaban
IL250168A0 (en) Crystalline form of 5 – chloro –n ( { (5s) – 2 – oxo – 3 – [ 4 – ( 5,6 – dihydro – 4h – [ 1,2,4 ] triazin-1-yl) phenyl] – 1, 3-oxazolidine-5-yl}methyl)thiophene-2-an innovative carboxamide and pharmaceutical preparations containing it
CU20080051A7 (es) Nueva forma polimórfica y la forma amorfa de 5-cloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morfolinil)-fenil]-1,3-oxazolidin-5-il}-metil)-2-tiofenocarboxamida

Legal Events

Date Code Title Description
B08F Application fees: dismissal - article 86 of industrial property law
B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)